Prelude Therapeutics (PRLD) Cash & Equivalents (2019 - 2026)

Prelude Therapeutics has disclosed Cash & Equivalents across 8 years of filings, most recently posting $84.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $84.8 million, up 91.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.8 million (up 91.37% YoY), and the FY2025 annual result was $35.3 million, up 113.44% from the prior year.
• Cash & Equivalents came in at $84.8 million for Q1 2026 at Prelude Therapeutics, up from $35.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $84.8 million in Q1 2026 to a low of $15.2 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $34.6 million (2022), against an average of $40.5 million.
• Across the five-year window, Cash & Equivalents slumped 84.66% in 2022 and jumped 234.48% in 2025, its largest moves.
• Prelude Therapeutics' Cash & Equivalents stood at $34.6 million in 2022, then retreated by 15.34% to $29.3 million in 2023, then plunged by 43.69% to $16.5 million in 2024, then surged by 113.44% to $35.3 million in 2025, then surged by 140.53% to $84.8 million in 2026.
• The last three Cash & Equivalents figures came in at $84.8 million (Q1 2026), $35.3 million (Q4 2025), and $50.8 million (Q3 2025), per Business Quant data.